American Society of Hirudotherapy

American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy

Research article published in Blood advances (2018)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Practice guidelineClinical TrialsWitt DM et al. · Blood advances, 2018

Abstract

BACKGROUND: Clinicians confront numerous practical issues in optimizing the use of anticoagulants to treat venous thromboembolism (VTE). OBJECTIVE: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians and other health care professionals in their decisions about the use of anticoagulants in the management of VTE. These guidelines assume the choice of anticoagulant has already been made. METHODS: ASH formed a multidisciplinary guideline panel balanced to minimize potential bias from conflicts of interest. The McMaster University GRADE Centre supported the guideline development process, including updating or performing systematic evidence reviews. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess evidence and make recommendations, which were subject to public comment. RESULTS: The panel agreed on 25 recommendations and 2 good practice statements to optimize management of patients receiving anticoagulants. CONCLUSIONS: Strong recommendations included using patient self-management of international normalized ratio (INR) with home point-of-care INR monitoring for vitamin K antagonist therapy and against using periprocedural low-molecular-weight heparin (LMWH) bridging therapy. Conditional recommendations included basing treatment dosing of LMWH on actual body weight, not using anti-factor Xa monitoring to guide LMWH dosing, using specialized anticoagulation management services, and resuming anticoagulation after episodes of life-threatening bleeding.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticlePractice Guideline
Indexed MeSH termsATP Binding Cassette Transporter, Subfamily BAdministration, OralAnticoagulantsCytochrome P-450 Enzyme SystemEvidence-Based MedicineHeparinHeparin, Low-Molecular-WeightHumansInternational Normalized RatioMedication AdherencePoint-of-Care SystemsVenous Thromboembolism

Summary

Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.

Why This Matters for Hirudotherapy

This American Society of Hematology (ASH) clinical practice guideline used the GRADE framework and systematic evidence reviews (supported by the McMaster University GRADE Centre) to issue 25 recommendations and 2 good-practice statements on optimizing anticoagulation once a drug has been chosen for venous thromboembolism (VTE), including a strong recommendation for patient self-management of INR with home point-of-care monitoring for vitamin K antagonist therapy and a strong recommendation against periprocedural low-molecular-weight heparin bridging. For hirudotherapy it frames the conventional pharmacologic anticoagulation landscape against which leech-derived anticoagulants (such as hirudin) and topical leech therapy in flap salvage are positioned, and underscores that systemic anticoagulant management is governed by rigorous, graded evidence. Caveat: this is a guideline synthesizing prior studies on systemic anticoagulant drugs for VTE; it does not study medicinal leeches or hirudotherapy and makes no claims about them, so it is context rather than direct evidence for leech treatment.

Citation

American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.

Witt DM et al. · Blood advances, 2018

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.